Company attributes
Other attributes
In over 50 years there was little development in the treatment of chronic kidney disease. At inRegen we are pioneers in the field of Chronic kidney treatment.
FDA awarded Fast Track Designation
REACT Potential health care cost off-set equals approximately $250K/patient/year
Partnership with the National Kidney Foundation (NKF) and the American Association of Kidney Patients (AAKP)
inRegen’s technology has the potential to restorekidney function by using the patient’s own (autologous) kidney cells. By contrast, organ transplantation from other donors (allogenic transplants) can be associated with organ rejection and failure. Further, the patient lives with the adverse effects of immunosuppression.
inRegen's patented technology uses multiple breakthroughs in manufacturing, automation, supply chain, and delivery technologies. While it has long been held that the body contains cells with regenerative power, inRegen's technology is able to identify these cells and harness them to create a specific repair, restoration and function improvements of chronically diseased kidneys on a commercial scale.
inRegen’s kidney restoration process begins with a patient’s biopsy. inRegen is able to identify the patient’s own healthy progenitor cells, and formulate them into a personalized product that can be injected into the damaged kidney for repair, regeneration and restoration of function. When the personalized product (REACT™) is injected into the patient’s diseased kidney, it is programmed to integrate into the damaged tissues and controlling inflammation, fibrosis and angiogenesis to form new functioning tissues and ultimately, a more healthy kidney.
